Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Patent Infringement:...

    Patent Infringement: Cadila Healthcare, two others prohibited from launching Linagliptin Metformin Hydrochloride tablets

    Meghna A SinghaniaBy Meghna A SinghaniaPublished On 2019-04-22T14:07:07+05:30  |  Updated On 2021-08-16T15:20:03+05:30

    AHMEDABAD: In a major setback, three Gujarat based pharmaceutical companies including Cadila Healthcare, West Coast Pharmaceutical Works Ltd and Maan Pharmaceuticals Ltd have been temporarily prohibited from manufacturing and launching in the market Linagliptin tablet and Fixed Dose Combination (FDC) of Linagliptin and Metformin Hydrochloride tablet over patent infringement of a German Company, suggests a media report. The formulations are indicative of treating Type-2 diabetes.


    The Commerical court has presently restricted the launch, make or sell of the said product by these drugmakers. The court has issued notices to all three companies and sought their replies by April 25.


    The move comes in following a lawsuit filed by the German Pharma giant, Boehringer Ingelheim Pharma GmbH & Co KG. The matter originated after the company learnt via media reports about Cadila Healthcare seeking a tentative licence from the US Health Regulators to export the drug and getting a nod from the U.S Food and Drugs Administration (USFDA). In October 2018, Cadila had reportedly informed the Indian bourses about the same.


    On learning this, Boehringer filed an application immediately under the Right to Information (RTI) Act to find out if the drug regulators had granted a license to the three Gujarat based companies to launch the diabetes medicine in the market.


    Boehringer has claimed a patent on Linagliptin Metformin Hydrochloride tablets which was obtained from the Controller of Patents in January 2009 and October 2010. The company claimed that it holds the patent for Linagliptin, which is valid for the coming three years. The local companies have been asked to not manufacture even a generic version of the drug or any other product covered by the German company's patent.


    Deliberating the case, the judge of the commercial court, Moolchand Tyagi, said that Boehringer Ingelheim has duly registered Linagliptin tablet and Fixed Dose Combination of Linagliptin + Metformin Hydrochloride tablets. The facts obtained under the RTI laws from the regulators of drugs disclosed that the drugmakers were about to launch the medicine, thus infringing on the patents of the German company.


    According to TOI, the judge further said, "In my considered view, the plaintiff has a prima facie case in its favour and balance of convenience also lies in its favour. If the plaintiff is not granted ex-parte ad interim injunction, it would cause irreparable loss to the plaintiff and further, it will cause prejudice to the rights of the plaintiff. Further delay in granting protection would cause hardship and defeat the object of the suit."


    Also Read: Sun Pharma arm gets relief from US court in patent infringement case

    blood sugar Boehringer Boehringer Ingelheim Boehringer pharma Cadila Healthcare Commercial Court diabetes diabetes drug diabetes medicine German patent Gujarat Hydrochloride tablets linagliptin Linagliptin Metformin Hydrochloride tablets Metformin Moolchand Tyagi patent Patent infringement pharma Pharma companies pharma news india RTI USFDA 
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X